Wolters Kluwer Pharma Solutions, Inc., a US-based provider of scientific information and analytics to professionals in the pharmaceutical and biotech fields, has added a new open access (OA) publishing option for authors submitting original research articles to the Adis line of pharmacology and pharmacotherapy journals - a total of 16 titles.
According to the company, Adis content is subject to rigorous, independent peer review before publication, and this practice will continue under the OA model. For more than 40 years, Adis journals were available only through pay-per-view or subscription. With immediate effect, researchers will increasingly have unrestricted, free access to a significant portion of content from new issues of these titles. For existing subscribers this will be free, additional content.
Popular journals in the high-impact portfolio include Clinical Pharmacokinetics, CNS Drugs, Drug Safety, and Adis' flagship title, Drugs. Under the new guidelines, OA articles are published online-only, and are accessible on AdisOnline and Ovid to read, copy, share and distribute for non-commercial purposes.
The OA format has been widely adopted by STM publishers in recent years as the model for new start-up journals, partly in response to market demand and partly due to the increasing difficult challenge of developing an audience of paid subscribers for a new title in a saturated marketplace. These new journals have been popular with authors who want to see their research made available as widely as possible, but increasingly they also demand an OA publishing option for recognised, high-impact journals with established readership. In June 2010, the company successfully transitioned the journal Drugs in R&D from subscription-only to fully OA, making it the first Adis journal to offer OA delivery.
Search for more Pharma related scientific journals
To access our daily STM news feed through your iPhone, iPad, or other smartphones, please visit www.myscoope.com for a mobile friendly reading experience.
